Alector, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Alector, Inc. (ALEC) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$142.76 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-25
- Alector, Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2025-12-31 was -$37.10M.
- Alector, Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2025-09-30 was -$34.67M.
- Alector, Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2025-06-30 was -$30.52M.
- Alector, Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2025-03-31 was -$40.47M.
- Alector, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$142.76M.
- Alector, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$118.92M.
- Alector, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$125.18M.
- Alector, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$130.06M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 3 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 6 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 9 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$37.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$71.77M derived: sum of 2 quarters · filed 2026-02-25 | -$102.29M derived: sum of 3 quarters · filed 2026-02-25 | -$142.76M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$34.67M 10-Q · filed 2025-11-06 | -$65.19M derived: sum of 2 quarters · filed 2025-11-06 | -$105.66M 10-Q · filed 2025-11-06 | -$107.69M derived: sum of 4 quarters · filed 2026-02-25 |
| 2025-06-30 | -$30.52M 10-Q · filed 2025-08-07 | -$71.00M 10-Q · filed 2025-08-07 | -$73.02M derived: sum of 3 quarters · filed 2026-02-25 | -$115.24M derived: sum of 4 quarters · filed 2026-02-25 |
| 2025-03-31 | -$40.47M 10-Q · filed 2025-05-08 | -$42.50M derived: sum of 2 quarters · filed 2026-02-25 | -$84.72M derived: sum of 3 quarters · filed 2026-02-25 | -$123.32M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-12-31 | -$2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$44.25M derived: sum of 2 quarters · filed 2026-02-25 | -$82.85M derived: sum of 3 quarters · filed 2026-02-25 | -$118.92M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$42.22M 10-Q · filed 2025-11-06 | -$80.82M derived: sum of 2 quarters · filed 2025-11-06 | -$116.89M 10-Q · filed 2025-11-06 | -$156.66M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$38.60M 10-Q · filed 2025-08-07 | -$74.67M 10-Q · filed 2025-08-07 | -$114.44M derived: sum of 3 quarters · filed 2025-08-07 | -$157.67M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$36.07M 10-Q · filed 2025-05-08 | -$75.84M derived: sum of 2 quarters · filed 2025-05-08 | -$119.06M derived: sum of 3 quarters · filed 2025-05-08 | -$116.30M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$39.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$82.99M derived: sum of 2 quarters · filed 2025-02-26 | -$80.22M derived: sum of 3 quarters · filed 2025-02-26 | -$125.18M 10-K · filed 2025-02-26 |
| 2023-09-30 | -$43.22M 10-Q · filed 2024-11-06 | -$40.45M derived: sum of 2 quarters · filed 2024-11-06 | -$85.41M 10-Q · filed 2024-11-06 | -$137.12M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $2.77M 10-Q · filed 2024-08-07 | -$42.19M 10-Q · filed 2024-08-07 | -$93.89M derived: sum of 3 quarters · filed 2025-02-26 | -$139.31M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$44.96M 10-Q · filed 2024-05-08 | -$96.66M derived: sum of 2 quarters · filed 2025-02-26 | -$142.08M derived: sum of 3 quarters · filed 2025-02-26 | -$131.15M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$51.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$97.12M derived: sum of 2 quarters · filed 2025-02-26 | -$86.20M derived: sum of 3 quarters · filed 2025-02-26 | -$130.06M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$45.41M 10-Q · filed 2023-11-07 | -$34.49M derived: sum of 2 quarters · filed 2023-11-07 | -$78.35M 10-Q · filed 2023-11-07 | -$133.96M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $10.93M 10-Q · filed 2023-08-03 | -$32.93M 10-Q · filed 2023-08-03 | -$88.54M derived: sum of 3 quarters · filed 2024-02-27 | $38.05M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$43.86M 10-Q · filed 2023-05-04 | -$99.47M derived: sum of 2 quarters · filed 2024-02-27 | $27.13M derived: sum of 3 quarters · filed 2024-02-27 | -$28.02M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$55.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $70.99M derived: sum of 2 quarters · filed 2024-02-27 | $15.84M derived: sum of 3 quarters · filed 2024-02-27 | -$36.33M 10-K · filed 2024-02-27 |
| 2021-09-30 | $126.60M 10-Q · filed 2022-11-08 | $71.45M derived: sum of 2 quarters · filed 2022-11-08 | $19.28M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$55.15M 10-Q · filed 2022-08-04 | -$107.32M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$52.17M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$190.23M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |